/DISCLAIMER · RESEARCH_COMPOUND

This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.

/VIP_VASOACTIVE_INTESTINAL_PEPTIDE
Peptide

VIP

Neuropeptide / Immunomodulatory Peptide

/HALF_LIFE
Very short in plasma (~1–2 minutes); effects may be prolonged with localized delivery or protected formulations.
/DELIVERY
Intranasal spray or nebulized/inhaled routes for airway studies; subcutaneous or intravenous bolus/infusion in systemic physiology models.

/WHAT_IT_IS

VIP (Vasoactive Intestinal Peptide) is a 28–amino acid neuropeptide widely distributed in the CNS, lungs, and gut. It exerts potent vasodilatory, bronchodilatory, and immunomodulatory effects and is studied for roles in airway tone, mucosal protection, and neuroimmune signaling.

/USAGE

Research on airway diseases (bronchodilation, mucus regulation), gastrointestinal motility/secretions and barrier function, neuroprotection, and immune modulation (anti-inflammatory, Th2/Treg bias).

/MECHANISM_OF_ACTION

Binds VPAC1/VPAC2 (class B GPCRs) to activate Gs→adenylate cyclase→cAMP/PKA signaling, relaxing smooth muscle, enhancing epithelial secretion, and modulating cytokines; rapidly degraded by peptidases (e.g., DPP-IV, neutral endopeptidase).

Reported Benefits

  • +Bronchodilation and airway smooth-muscle relaxation
  • +Vasodilation and improved microcirculatory flow
  • +Reduced pro-inflammatory cytokine signaling
  • +Support for epithelial barrier integrity and mucus regulation
  • +Neuroprotective/neuromodulatory effects in CNS models

Reported Side Effects

  • Flushing and warmth
  • Headache or lightheadedness
  • Transient hypotension or tachycardia (dose-dependent)
  • Nasal/throat irritation with intranasal or inhaled use
  • GI cramping or diarrhea in sensitive subjects

/STACKED_WITH

Thymosin Alpha 1 (immune-modulatory pairing)BPC-157 (adjacent mucosal/tissue repair models)Hyaluronic-acid or hydrogel carriers (stability/retention in topical or intranasal research)

/RESEARCH_NOTES

Owing to rapid enzymatic degradation, protocols often explore stabilized analogs (e.g., aviptadil) or delivery vehicles to extend residence time. Outcomes typically track spirometry/airway responsiveness, hemodynamics, cytokine panels, and epithelial barrier metrics.

/REFERENCE

https://en.wikipedia.org/wiki/Vasoactive_intestinal_peptide

/RELATED

/TRACK_THIS

Browse all 89 in the app.

MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.

Last reviewed: 2026-06-04 · Reference only. Not medical advice. Consult a qualified physician.